Hepatocyte delivery vehicle for delivery of glargine insulin to a mammal
AssigneeSDG, Inc.
InventorsJohn Lau, W. Geho
Life of this patent
Estimating the term…
Abstract
The instant invention is drawn to a hepatocyte targeted composition comprising a mixture of free glargine insulin and glargine insulin associated with a water insoluble target molecule complex, wherein the complex comprises multiple linked individual units and a supra-molecular lipid construct matrix. Glargine insulin is present within the complex in at least one form wherein the glargine insulin has a positive charge which interacts with a negative charge on the complex. The invention also includes methods for the manufacture of the composition and methods of managing blood glucose levels in individuals with Type I and Type II diabetes.
Claims22
A hepatocyte-targeting composition comprising:
- a. free glargine insulin;
- and
- b. glargine insulin associated with a water-insoluble target molecule complex;
- wherein said target molecule complex is comprised of a combination of:
- a. multiple linked individual units, said individual units comprising:
- i. at least one bridging component selected from the group consisting of a transition element, an inner transition element, and a neighbor element of said transition element;
- and
- ii. a complexing component;
- and
- b. a supra-molecular lipid construct matrix comprising at least one lipid component;
- provided that when said transition element is chromium, a chromium target molecule complex is created;
- further wherein said target molecule complex comprises a negative charge.
A method of increasing the bioavailability of glargine insulin in a patient, said method comprising:
- administering glargine insulin in a hepatocyte-targeting composition, said composition comprising free glargine insulin and glargine insulin associated with a water insoluble target molecule complex,
- wherein said complex comprises multiple linked individual units and a supra-molecular lipid construct matrix containing a negative charge, said multiple linked individual units comprising:
- (a) a bridging component selected from the group consisting of a transition element, an inner transition element, a neighbor element of said transition element and a mixture of any of the foregoing elements, (b) a complexing component, provided that when said transition element is chromium, a chromium target molecule complex is created,
- wherein said multiple linked individual units are combined with said supra-molecular lipid construct matrix, wherein said insulins are associated with said target molecule complex that contains a negative charge;
- thereby the association between glargine insulin and said water insoluble target molecule complex is altered within said patient to form new structures associated with said glargine insulin, wherein said new structures are present in soluble and insoluble forms and are delivered to sites of insulin activity.
A kit for treating Type I or Type II diabetes in a mammal, said kit comprising glargine insulin and a water insoluble target molecule complex, wherein said complex comprises multiple linked individual units and a supra-molecular lipid construct matrix containing a negative charge, said multiple linked individual units comprising:
- a bridging component selected from the group consisting of a transition element, an inner transition element, a neighbor element of said transition element and a mixture of any of the foregoing elements, and a complexing component, provided that when said transition element is chromium, a chromium target molecule complex is created, wherein said multiple linked individual units are combined with said supra-molecular lipid construct matrix, wherein the glargine insulin is associated with a target molecule complex, wherein said complex comprises a negative charge, said kit further comprising a physiological buffered solution, an applicator, and an instructional material for the use thereof.
Dependencies are inferred from the claim text.